Plain-English translation of NCT06970743 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares a new medication called against standard chemotherapy treatments for people with chronic lymphocytic leukemia or small lymphocytic lymphoma (types of blood cancer) that have stopped responding to previous medications. About 150 people will be randomly assigned to either receive the new medication or one of two standard treatment options. The trial is measuring whether the medication helps people live longer without their cancer getting worse.
People with this type of blood cancer often see their disease stop responding to current treatments, and they urgently need new options to help them live longer and manage their symptoms. This trial tests whether this medication could offer better results than the existing standard treatments.
If you qualify, you'll be randomly assigned to either take the new medication daily until your cancer progresses or stops responding, or receive one of two standard chemotherapy treatments given over six cycles (about 6 months). Your progress will be monitored regularly with scans and blood tests. If your cancer worsens on the standard treatment, you may have the option to switch to the new medication. The trial is taking place in Mainland China and Taiwan.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
China